Ann: Trading Halt, page-41

First 41 Last

Share
Profile

Follow
Glitterati

10,345 Posts.

2811

04/12/20

21:38

Post #: 49359577
Share

Originally posted by comincon: ↑

Interestingly esketamine, (ketamine) now with approval in the US as well as the UK and Europe, seems to show the psychedelic door is well and truly opening for this member of the mind altering family.

'Spravato' ( product branded esketamine deveoped by Janssen Pharmaceutica in 2019) received FDA & EMA approval for use.

Ketamine is arguably the most rigorously studied psychedelic substance backed by many multiple clinical studies since the 1980s' and widely believed to be one of the most effective agents against treatment resistive depression.
'Spravato' could potentially return the company (Janssen Pharmaceutica) hundreds of millions of dollars through this treatment pathway alone.

on the google machine ....

check out the website - this is really exiting stuff ( and its just esketamine....only one within the psychedelic family)
SPRAVATO® (esketamine): A Prescription Nasal Spray | SPRAVATO®

Lots to like with todays news as many have suggested already

not intended as financial advice - dyor

Expand

Good one C, really looking forward to seeing the detail around this next week
I'm not necessarily locked into thinking this will revolve around Psilocybin, it could very well be something else entirely, I always expect something out of left field from these guys

All shall be revealed!

IHL Price at posting: 14.5¢ Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

IRE

Iress runs 'hot' for Wealth Within's stock tips